Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 9.67
IGXT's Cash to Debt is ranked lower than
58% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. IGXT: 9.67 )
Ranked among companies with meaningful Cash to Debt only.
IGXT' s 10-Year Cash to Debt Range
Min: 0.07  Med: 9999.00 Max: No Debt
Current: 9.67
Equity to Asset 0.74
IGXT's Equity to Asset is ranked higher than
56% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. IGXT: 0.74 )
Ranked among companies with meaningful Equity to Asset only.
IGXT' s 10-Year Equity to Asset Range
Min: -0.4  Med: 0.70 Max: 0.9
Current: 0.74
-0.4
0.9
Interest Coverage No Debt
IGXT's Interest Coverage is ranked higher than
69% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IGXT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IGXT' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 3
Z-Score: 10.74
M-Score: -0.45
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -64.16
IGXT's Operating margin (%) is ranked higher than
51% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. IGXT: -64.16 )
Ranked among companies with meaningful Operating margin (%) only.
IGXT' s 10-Year Operating margin (%) Range
Min: -855  Med: -206.59 Max: -87.43
Current: -64.16
-855
-87.43
Net-margin (%) -65.86
IGXT's Net-margin (%) is ranked higher than
51% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. IGXT: -65.86 )
Ranked among companies with meaningful Net-margin (%) only.
IGXT' s 10-Year Net-margin (%) Range
Min: -630  Med: -209.69 Max: -105.24
Current: -65.86
-630
-105.24
ROE (%) -27.51
IGXT's ROE (%) is ranked higher than
52% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. IGXT: -27.51 )
Ranked among companies with meaningful ROE (%) only.
IGXT' s 10-Year ROE (%) Range
Min: -1461.46  Med: -166.60 Max: -36.45
Current: -27.51
-1461.46
-36.45
ROA (%) -22.46
IGXT's ROA (%) is ranked higher than
53% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. IGXT: -22.46 )
Ranked among companies with meaningful ROA (%) only.
IGXT' s 10-Year ROA (%) Range
Min: -193.99  Med: -100.55 Max: -27.93
Current: -22.46
-193.99
-27.93
ROC (Joel Greenblatt) (%) -144.06
IGXT's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. IGXT: -144.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IGXT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -808.25  Med: -311.27 Max: -167.9
Current: -144.06
-808.25
-167.9
Revenue Growth (3Y)(%) 44.20
IGXT's Revenue Growth (3Y)(%) is ranked higher than
89% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. IGXT: 44.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IGXT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -26.30 Max: 44.2
Current: 44.2
0
44.2
EBITDA Growth (3Y)(%) -20.60
IGXT's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. IGXT: -20.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IGXT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: -7.20 Max: 122.4
Current: -20.6
0
122.4
EPS Growth (3Y)(%) -20.60
IGXT's EPS Growth (3Y)(%) is ranked lower than
66% of the 417 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. IGXT: -20.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IGXT' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -14.50 Max: 141
Current: -20.6
0
141
» IGXT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IGXT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 6.97
IGXT's Forward P/E is ranked higher than
92% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 24.10 vs. IGXT: 6.97 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 8.43
IGXT's P/B is ranked lower than
71% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. IGXT: 8.43 )
Ranked among companies with meaningful P/B only.
IGXT' s 10-Year P/B Range
Min: 4.63  Med: 11.20 Max: 117
Current: 8.43
4.63
117
P/S 19.67
IGXT's P/S is ranked lower than
62% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. IGXT: 19.67 )
Ranked among companies with meaningful P/S only.
IGXT' s 10-Year P/S Range
Min: 6.25  Med: 21.71 Max: 98.5
Current: 19.67
6.25
98.5
Current Ratio 3.59
IGXT's Current Ratio is ranked lower than
56% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. IGXT: 3.59 )
Ranked among companies with meaningful Current Ratio only.
IGXT' s 10-Year Current Ratio Range
Min: 0.66  Med: 4.67 Max: 11.6
Current: 3.59
0.66
11.6
Quick Ratio 3.59
IGXT's Quick Ratio is ranked lower than
54% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. IGXT: 3.59 )
Ranked among companies with meaningful Quick Ratio only.
IGXT' s 10-Year Quick Ratio Range
Min: 0.66  Med: 4.67 Max: 11.6
Current: 3.59
0.66
11.6
Days Sales Outstanding 13.45
IGXT's Days Sales Outstanding is ranked higher than
89% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. IGXT: 13.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGXT' s 10-Year Days Sales Outstanding Range
Min: 55.44  Med: 159.91 Max: 390.59
Current: 13.45
55.44
390.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.75
IGXT's Price/Net Cash is ranked lower than
71% of the 428 Companies
in the Global Biotechnology industry.

( Industry Median: 8.00 vs. IGXT: 14.75 )
Ranked among companies with meaningful Price/Net Cash only.
IGXT' s 10-Year Price/Net Cash Range
Min: 8  Med: 14.75 Max: 32.25
Current: 14.75
8
32.25
Price/Net Current Asset Value 14.75
IGXT's Price/Net Current Asset Value is ranked lower than
72% of the 508 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. IGXT: 14.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
IGXT' s 10-Year Price/Net Current Asset Value Range
Min: 5.33  Med: 12.88 Max: 50
Current: 14.75
5.33
50
Price/Tangible Book 8.43
IGXT's Price/Tangible Book is ranked lower than
63% of the 688 Companies
in the Global Biotechnology industry.

( Industry Median: 5.82 vs. IGXT: 8.43 )
Ranked among companies with meaningful Price/Tangible Book only.
IGXT' s 10-Year Price/Tangible Book Range
Min: 5.33  Med: 11.00 Max: 95
Current: 8.43
5.33
95
Price/Median PS Value 0.90
IGXT's Price/Median PS Value is ranked higher than
65% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. IGXT: 0.90 )
Ranked among companies with meaningful Price/Median PS Value only.
IGXT' s 10-Year Price/Median PS Value Range
Min: 0.29  Med: 0.98 Max: 4.02
Current: 0.9
0.29
4.02
Earnings Yield (Greenblatt) (%) -3.90
IGXT's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. IGXT: -3.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IGXT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -6.1  Med: 0.00 Max: 0
Current: -3.9
-6.1
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:IGX.Canada,
Intelgenx Technologies Corp., was incorporated in Delaware on July 27, 1999. The Company is a drug delivery company. It is engaged in the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies. Its product development efforts are based upon three platform technologies: Versafilm- an oral film technology, VersaTab- a multilayer tablet technology and AdVersa- a mucoadhesive tablet technology. The Oral Film technology consists of a thin (25-35 micron) polymeric film comprised of United States Pharmacopeia (USP) components that are approved by the FDA for use in food, pharmaceutical, and cosmetic products. Its multilayer tablet technology allows for the development of oral controlled-release products. The mucoadhesive tablet is a drug delivery system capable of adhering to the oral mucosa and releasing the drug onto the site of application at a controlled rate. The Company's product portfolio includes a blend of generic and branded products based on its proprietary delivery technology. Some of its products are INT0001/2004, INT0004/2006, INT0007/2006, and among others. The Company competes with pharmaceutical industries. Some of its competitors include Monosol Rx, Tesa-Labtec GmbH, BioDelivery Sciences International, Inc and LTS Lohmann Therapy Systems Corp. It is subject to change in governmental regulations, healthcare legislations, availability of financing, patent litigation and other factors.
» More Articles for IGXT

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Jul 20 2015
IntelGenx Appoints Andre Godin as New Executive Vice-President and Chief Financial Officer Jul 20 2015
INTELGENX TECHNOLOGIES CORP. Financials May 22 2015
10-Q for IntelGenx Technologies Corp. May 16 2015
2015-05-14 IntelGenx Reports Q1, 2015 Results and Provides Corporate Development Update May 15 2015
2015-05-13 IntelGenx Announces Management Changes May 14 2015
IntelGenx Reports Q1, 2015 Results and Provides Corporate Development Update May 14 2015
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events May 14 2015
IntelGenx Announces Management Changes May 13 2015
2015-05-05 IntelGenx Confirms Execution of Lease and Construction Agreements May 05 2015
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events May 05 2015
IntelGenx Confirms Execution of Lease and Construction Agreements May 05 2015
2015-05-04 IntelGenx to Report 2015 First Quarter Update Call on May 15, 2015 May 04 2015
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events May 04 2015
IntelGenx to Report 2015 First Quarter Update Call on May 15, 2015 May 04 2015
2015-04-22 IntelGenx Provides Q1, 2015 Update on Sales of Forfivo XL(R) Apr 22 2015
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Apr 22 2015
2015-04-16 IntelGenx Announces Analyst Coverage Initiated by Singular Research Apr 16 2015
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Apr 16 2015
INTELGENX TECHNOLOGIES CORP. Files SEC form 8-K, Other Events Apr 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK